Abby Hardy, Author at BioTuesdays

Developments

LENZ Therapeutics, Graphite Bio in merger accord

Closely-held LENZ Therapeutics and Graphite Bio (NASDAQ:GRPH) entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company, which will focus on advancing LENZ’...

November 15, 2023

Developments

IntelGenx gets approval for Phase 2 Montelukast VersaFilm trial in Parkinson’s disease

IntelGenx (TSX:IGX; OTCQB:IGXT) reported that the Swedish Medical Products Agency, the Swedish Ethical Review Authority, and the Regional Biobank Centre approved the company’s planned clinical study to investigate the...

November 14, 2023

Feature

Intrinsic Medicine developing new drugs for gut-immune-brain axis disorders

Closely-held Intrinsic medicine is developing new drugs for diseases that are linked to the disordered interaction of the gut microbiome, the immune system and the nervous system.

November 14, 2023

Developments

Hepion’s rencofilstat demonstrates significant reduction in liver stiffness in patients with advanced MASH liver disease

Hepion Pharmaceuticals (NASDAQ:HEPA) presented new data from its Phase 2 ALTITUDE-NASH trial demonstrating that 17 weeks of rencofilstat treatment significantly reduced liver stiffness in subjects with advanced F3...

November 13, 2023

Markets

Brookline starts Annovis Bio at buy; PT $35

Brookline Capital Markets initiated coverage of Annovis Bio (NASDAQ:ANVS) with a “buy” rating and price target of $35. The stock was quoted at $5.85 midday on Nov. 10. Annovis is developing treatments for...

November 10, 2023

Developments

Elucid raises $80-million in Series C round

Closely-held Elucid raised $80-million to drive the commercialization of its AI-powered cardiovascular diagnostic tools. The round was led by Elevage Medical Technologies. Elucid’s FDA-cleared software is a non-invasive...

November 9, 2023

Markets

AGP ups Myomo to buy; PT $4.60 from $2

Alliance Global Partners upgraded Myomo (NYSE:MYO) to “buy” and raised its price target to $4.60 from $2. The stock was quoted at $1.85 midday on Nov.8. Myomo develops and markets the MyoPro product line of lightweight...

November 8, 2023

Feature

Rainhouse’s CNC machining expertise supporting specialty medical device manufacturing

Closely-held Rainhouse Manufacturing, a company specializing in computer numerical control (CNC) machining, quality assurance, and electronic manufacturing, is working with companies to make their medical device designs...

November 7, 2023

Developments

Profound Medical’s TULSA gets device-intensive status; CMS extension of temporary C Code to ambulatory surgical center setting

Profound Medical (NASDAQ:PROF; TSX:PRN) reported that the U.S. Centers for Medicare and Medicaid Services (CMS) has expanded TULSA’s HCPCS C code, C9734, for use in the ambulatory surgical center (ASC) setting...

November 3, 2023

Feature

SeaStar Medical prepares for FDA approval of device targeting treatment of pediatric acute kidney injury

SeaStar Medical (NASDAQ: ICU) expects an FDA Approval Order in the coming months for the company's Selective Cytopheretic Device (SCD) Pediatric (SCD-PED) under a humanitarian device exemption (HDE).

October 31, 2023

Author - Abby Hardy

LENZ Therapeutics, Graphite Bio in merger accord

IntelGenx gets approval for Phase 2 Montelukast VersaFilm trial in Parkinson’s disease

Intrinsic Medicine developing new drugs for gut-immune-brain axis disorders

Hepion’s rencofilstat demonstrates significant reduction in liver stiffness in patients with advanced MASH liver disease

Brookline starts Annovis Bio at buy; PT $35

Elucid raises $80-million in Series C round

AGP ups Myomo to buy; PT $4.60 from $2

Rainhouse’s CNC machining expertise supporting specialty medical device manufacturing

Profound Medical’s TULSA gets device-intensive status; CMS extension of temporary C Code to ambulatory surgical center setting

SeaStar Medical prepares for FDA approval of device targeting treatment of pediatric acute kidney injury

General

More